Cantor Fitzgerald restated their overweight rating on shares of Soleno Therapeutics (NASDAQ:SLNO – Free Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $19.00 price target on the stock.
Soleno Therapeutics Stock Up 1.8 %
Soleno Therapeutics stock opened at $4.98 on Thursday. The firm has a market cap of $49.76 million, a PE ratio of -1.64 and a beta of 0.11. Soleno Therapeutics has a 52-week low of $0.85 and a 52-week high of $6.20. The company’s 50 day moving average is $4.78 and its two-hundred day moving average is $3.97.
Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) last released its earnings results on Tuesday, August 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.11). On average, equities research analysts anticipate that Soleno Therapeutics will post -2.34 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Soleno Therapeutics
About Soleno Therapeutics
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
- Five stocks we like better than Soleno Therapeutics
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 8/28 – 9/1
- How to Invest in Biotech Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Breakout Stocks: What They Are and How to Identify Them
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.